Dana-Farber

Dana-Farber Cancer Institute - a leading center for expert, compassionate cancer care and advanced research.
Appts: 877-442-3324 |

[Dana-Farber @DanaFarber]

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.

In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.

While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.

As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”

Congratulations to the researchers and patients who made this important progress possible. 👏👏👏

Video Courtesy: @asco

[Dana-Farber News @DanaFarberNews]

Dana-Farber research supports FDA approval of pembrolizumab-belzutifan combination for higher-risk clear cell kidney cancer after surgery. Research led by @DrChoueiri of @DanaFarber_GU

Read more here: https://t.co/DvEWSBikoe

[Dana-Farber @DanaFarber]

Congratulations to both Hakim Lakhani and Sarah Kadish on being recognized on Becker's Healthcare’s 145 Patient Safety Experts to Know 2026 list. View the full list below. ⬇️ https://t.co/NMgC8YXjpG

[Dana-Farber @DanaFarber]

As treatment options continue to evolve in follicular lymphoma and marginal zone lymphoma, CD3/CD20 bispecific antibodies are showing real promise. Reid Merryman, MD, shares the latest trial updates and what they may mean for patients and clinicians: https://t.co/ZQ9PaBk2Bj

[Dana-Farber @DanaFarber]

Thank you to the Yawkey Foundation for its historic $50M commitment to support our future cancer hospital and the Future of Cancer Care Fund. This extraordinary gift will help advance groundbreaking research, innovative treatments, and patient-centered care for years to come.

Read more: https://t.co/X5X405FCV5

[Dana-Farber News @DanaFarberNews]

In People magazine: From his hospital bed, Robbie Fox and Kelli Peters, both age 27, said “I do” just 10 days before he succumbed to Ewing sarcoma, a rare cancer that forms in bone or soft tissue. The couple got engaged in March 2025, after Fox went into remission following treatment at @DanaFarber. Read more: https://t.co/JLCkItgplW

[Dana-Farber @DanaFarber]

Congratulations to Shail Maingi, MD, on being named to the 2026 Curve Magazine Powerlist, a publicly-nominated list of impactful LGBTQ+ women and nonbinary changemakers. Maingi is honored for her contributions in stem, education and research. Learn more: https://t.co/dbubgrMInM

[Toni Choueiri, MD @DrChoueiri]

In 1948, Sidney Farber and colleagues published his work in @NEJM that helped open the door to modern chemotherapy.

Seeing that history from the same institution — especially after a remarkable #ASCO26 with major plenary contributions and @NEJM papers from @DanaFarber — is humbling.

A powerful reminder that progress in oncology is built across generations: by patients, scientists, clinicians, and teams who keep asking what might be possible.

[Dana-Farber @DanaFarber]

New medicines called RAS inhibitors are dramatically changing the future of pancreatic cancer treatment. Our researchers are helping lead clinical trials studying these promising therapies for patients with pancreatic cancer. Learn how RAS inhibitors work, who may benefit and what and research is underway. ⬇️ https://t.co/MA7gr9O31t

[Boston 25 News @boston25]

Dana-Farber: New drug shows promise as potential breakthrough in pancreatic cancer treatment https://t.co/xaC37iPADU

[Dana-Farber @DanaFarber]

Thanks to new clinical trial results and novel targeted agents, patients with chronic lymphocytic leukemia now have several options for first-line therapy. Explore the leading treatment approaches: https://t.co/OUmDfRxhh6

[Dana-Farber @DanaFarber]

Kathleen Keavany, MHA, was recently named senior vice president of Ambulatory Care. This position was newly created to gain strategic leadership and operational oversight of ambulatory services. In partnership with executive and clinical leadership, she helps ensure exceptional care across all of our outpatient clinical programs through innovative practices.

[OncLive.com @OncLive]

Attending ILCC? Make room on your schedule.

This Ask the Expert event is built for clinicians managing advanced NSCLC, with a deep dive into TROP2-directed ADCs — the latest evidence, biomarker considerations, and sequencing strategies that shape real treatment decisions.

📅 July 23, 2026
🕒6:30 PM PT
📍Hyatt Regency Huntington Beach Resort and Spa | Huntington Beach, CA

Register: https://t.co/DSW5KRSZ29

[Dana-Farber @DanaFarber]

Research by Lakshmi Nayak, MD, and Caron Jacobson, MD, MMSc, helped advance a major milestone in relapsed/refractory primary CNS lymphoma: an @US_FDA label update for axicabtagene ciloleucel, the first CAR T-cell therapy for this disease. Learn more about the science behind this milestone: https://t.co/2kJZwvFxlh

[Dana-Farber @DanaFarber]

Wrapping up #ASCO26 with @HeadNeckMD delivering phase 1 interim analysis results on emiltatug ledadotin, a targeted antibody-drug conjugate being studied for patients with aggressive adenoid cystic carcinoma.

[Dana-Farber News @DanaFarberNews]

“I am thrilled to see these results be positive. I am hopeful that this will become a third treatment option for patients.” @DanaFarber's Dr. Mary-Ellen Taplin talks with @statnews about the PROTEUS trial in prostate cancer presented as a plenary at #ASCO26.

https://t.co/OrKaLYvlz2

CC: @DanaFarber_GU

[Dana-Farber News @DanaFarberNews]

"New Game-Changing Pancreatic Cancer Treatment" - Dr. Brian Wolpin of @DanaFarber sits down with Erika Edwards and NBC Nightly News to discuss a new hope for treating pancreatic cancer. Dr. Wolpin presented the study results to a standing ovation today at #ASCO26.
https://t.co/U49mIdCByB

@NBCNews @DanaFarber_Hale

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Dana-Farber @DanaFarber]

Please join us in congratulating @IrenemGhobrial, MD, and @DrHaddadRobert on receiving @OncLive’s Giants of Cancer Care award — an honor that celebrates the visionaries whose groundbreaking discoveries, fearless innovation, and relentless dedication have transformed the landscape of oncology.

[Dana-Farber @DanaFarber]

“This is the first RAS inhibitor evaluated in a large, randomized trial for patients with pancreatic cancer, and it demonstrates how important an impact these novel medicines are likely to have on the treatment of the disease. It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life,” said Wolpin. #ASCO26

[Dana-Farber @DanaFarber]

Brian Wolpin, MD, MPH, presents positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy. #ASCO26